Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

6.260 +0.030 (+0.48%)
Streaming Delayed Price Updated: 3:03 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Agenus inc (AGEN) Q2 2021 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Agenus Q2 Earnings
Shares of Agenus (NASDAQ:AGEN) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 32.14% over... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Why Agenus Stock Sank on Tuesday
A top company executive is stepping down in the very near future. 
Via The Motley Fool
Why Agenus Stock Is Marching Higher Today
The biotech took a major step toward becoming a commercial-stage cancer company. 
Via The Motley Fool
Exposures Product Safety
34 Stocks Moving In Thursday's Mid-Day Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger... 
Via Benzinga
What's Going On With Agenus Stock Today?
Agenus Inc (NASDAQ:AGEN) shares are trading higher by 35.2... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
50 Biggest Movers From Yesterday
Gainers Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share. Midatech Pharma plc (NASDAQ... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer
The FDA has accepted for review Agenus Inc's (NASDAQ: AGEN) marketing application seeking approval for balstilimab for recurrent or metastatic cervical cancer... 
Via Benzinga
Exposures Product Safety
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
75 Biggest Movers From Yesterday
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade... 
Via Benzinga
Why Agenus Stock Is Jumping Today
There was some positive news, but it probably wasn't a huge catalyst for the stock. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%
The integration of technology and successful clinical trials for treating critical ailments have boosted Wall Street’s optimism about several biotech stocks. Analysts expect Bionano, Cerus, Agenus and... 
Via Talk Markets
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
Exposures COVID-19
2 Grossly Undervalued Biotech Stocks That Could Double Your Money
Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt. 
Via The Motley Fool
Exposures COVID-19
Why Agenus Stock Skyrocketed Today
The biotech announced a big licensing deal with Bristol Myers Squibb. 
Via The Motley Fool
58 Biggest Movers From Yesterday
Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI)... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Turns Negative; Ultralife Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 0.39% to 34,192.78 while the NASDAQ fell 0.11% to 13,364.14. The S&P also fell, dropping 0.42% to 4,145.60. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Onconova Therapeutics (NASDAQ:ONTX) shares moved upwards by 41.84% to $0.88 during Tuesday's regular session. As of 12:30 EST, this security is trading at a... 
Via Benzinga
Mid-Day Market Update: TOMI Environmental Solutions Falls After Q1 Results; Agenus Shares Jump
Midway through trading Tuesday, the Dow traded down 0.16% to 34,272.59 while the NASDAQ rose 0.69% to 13,470.97. The S&P also rose, gaining 0.03% to 4,164.63. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agenus Inc. (NASDAQ: AGEN) shares surged 33.4% to $4.35. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Walmart Tops Q1 Expectations
Following the market opening Tuesday, the Dow traded down 0.23% to 34,248.63 while the NASDAQ rose 0.39% to 13,431.72. The S&P also fell, dropping 0.13% to 4,158.02. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors
Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will... 
Via Benzinga
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
From Bristol-Myers Squibb
Via Business Wire
Why Agenus Stock Tumbled Today
The company announced mixed Q1 results on a day when many biotech stocks were sinking. 
Via The Motley Fool
Agenus Inc (AGEN) Q1 2021 Earnings Call Transcript
AGEN earnings call for the period ending April 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.